Drugs / Neuropeptide Y
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04838678 | Jul 2021 → Dec 2026 expected | hypertensive disorder, obesity disorder | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01533519 | Dec 2012 → Jan 2016 | post-traumatic stress disorder | James Murrough | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02639637 | Dec 2015 → Jun 2017 | type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04071600 Comparator | Nov 2019 → Oct 2022 | acute stress disorder, post-traumatic stress disorder | New York Medical College | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neuropeptide Y | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02639637 ↗ |
| Modality | Peptide | “neuropeptide Y, an endogenous peptide” NCT02639637 ↗ |
| Route | Intranasal | “We examined the tolerability and anxiolytic efficacy of neuropeptide Y administered via an intranasal route in patients with posttraumatic stress disorder.” PMID 29186416 ↗ Jan 2018 |